Published On: Tue, Feb 28th, 2017

Perrigo shares down 10% after company reports loss, sells Tysabri Drug Royalties

Perrigo John Hendrickson

 

Perrigo announced on Monday that it had signed a definitive agreement to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to RPI Finance Trust, an affiliate of Royalty Pharma for up to $2.85 billion.

$2.2 billion in cash at closing and up to $650 million in potential milestone payments based upon future global net sales of Tysabri in 2018 and 2020. This transaction is expected to close within 30 business days, subject to certain specified closing deliverables.

Pharmaceuticals company Perrigo’s share price on Tuesday morning is down 10+% on the Tel Aviv Stock Exchange.

Perrigo acquired the rights to the Tysabri royalty stream through its 2013 acquisition of Elan Corporation plc.

Starboard Value LP, an activist investment fund which compelled Perrigo to replace five directors, has forced the company a sale of one of its most important assets.

Perrigo reported a preliminary 2016 loss in a range of $28.85 and $29 a share, and preliminary adjusted earnings per diluted share in the range of $7.10 a share and $7.25 a share.

Perrigo said it expects 2017 reported earnings per share to be in the range of $3.39 to $3.74, and adjusted earnings per diluted share to be in the range of $6.30 to $6.65.

Perrigo also announced that it was postponing release of its full financial statements for 2016, and that it would lay off 750 employees, about 14% of its non-production workforce.

In an additional development, the company also appointed Ron Winowiecki as acting chief financial officer, effective immediately, after the resignation of Judy L. Brown, who joined another pharmaceutical company.

Perrigo CEO John T. Hendrickson said of the Tysabri sale, “Today’s announcement is the result of Perrigo’s review of strategic alternatives for the Tysabri royalty stream announced in November 2016. We are pleased to have reached an agreement that maximizes the value of this non-core asset. While dilutive to adjusted EPS, the significant upfront cash component will allow us to de-lever our balance sheet, which supports our investment grade financial policy, and better positions Perrigo to pursue our strategic plan. This transaction also furthers our stated strategy to enhance our portfolio and focus on our consumer-facing and Rx businesses.”

 

Read more about: , , , ,

About the Author

Wordpress site Developed by Fixing WordPress Problems